Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD. is a leading contract research and testing organization, providing bio/pharmaceutical companies an integrated scientific, technical, and regulatory expertise to support all stages of drug development and manufacturing process. Our service portfolio includes preclinical and clinical research; and cGMP laboratory services viz., method development, microbiology, stability testing, extractables & leachables, process validation, quality control, physical characterization etc. In our 40 years of journey, we have gained in-depth scientific and technical expertise through working with a variety of molecules and formulations in different therapeutic areas. We support the needs of more than 300 bio/pharmaceutical companies across the globe, from virtual to large pharma and biopharma, through a wide range of expertise. Our team of 1300+ professionals constantly endeavors to provide timely scientific solutions and services to help customers manage their drug development and manufacturing processes more efficiently without compromising quality. We have a track record of strict compliance with regulatory requirements (cGMP, GLP, GCP) and Standards (ISO 17025, ISO 15189, ISO 9001), and have undergone over 40 regulatory audits successfully from regulatory agencies across the globe, including DCGI, NGCMA, USFDA, WHO, MHRA, ANSM, ANVISA, BfArM and DRAs of Denmark, Sweden, Portugal, and Ukraine.
| Website | https://www.vimta.com/ |
| Revenue | $38.1 million |
| Employees | 1,831 (641 on RocketReach) |
| Founded | 1984 |
| Address | 142, IDA, Phase II, Cherlapally, Hyderabad, Telangana 500051, IN |
| Industry | Research Services, Discovery Tools (Healthcare), Drug Discovery |
Looking for a particular Vimta Labs Ltd employee's phone or email?
The Vimta Labs Ltd annual revenue was $38.1 million in 2026.
Upendra Bhatnagar is the President- Preclinical Business of Vimta Labs Ltd.
641 people are employed at Vimta Labs Ltd.
Vimta Labs Ltd is based in Hyderabad, Telangana.